GlassScriptPhysician profile
Dynara Mirone
NPI 1003538810
$1,855.34
in general payments reported to CMS, 2019-2025
19 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $106 · 2023: $1,007 · 2024: $508 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $522.48 | 2022-2024 | Wegovy, Rybelsus, Ozempic |
| Dexcom, INC. | $291.98 | 2023-2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Medtronic, INC. | $125.34 | 2023 | Minimed 780g |
| Horizon Therapeutics Plc | $124.57 | 2023 | Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.75 | 2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $97.85 | 2024 | Eliquis |
| Cequr Corporation | $97.64 | 2023 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $90.51 | 2024-2025 | |
| Amgen INC. | $88.98 | 2023-2024 | Repatha, Otezla |
| Tandem Diabetes Care, INC. | $74.58 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $55.89 | 2024 | |
| Lilly USA, LLC | $49.08 | 2024-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $28.27 | 2024 | |
| Boston Scientific Corporation | $20.17 | 2024 | Watchman Flx |
| Ars Pharmaceuticals Operations, INC. | $19.32 | 2025 | Neffy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.91 | 2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $16.86 | 2024 | Trintellix |
| Phathom Pharmaceuticals, INC. | $16.51 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $14.65 | 2024 | Arexvy, Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dynara Mirone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.